2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

ADC human IgG1

" in MedChemExpress (MCE) Product Catalog:

38

Inhibitors & Agonists

4

Fluorescent Dyes

25

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-164153
    ADC Control Human IgG1-vcMMAE (solution)

    		Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    ADC Control Human IgG1-vcMMAE (solution) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
    ADC Control Human IgG1-vcMMAE (solution)
  • HY-164152A
    ADC Control Human IgG1-Deruxtecan (DAR 8)

    		Antibody-Drug Conjugates (ADCs) Topoisomerase Cancer
    ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
    ADC Control Human IgG1-Deruxtecan (DAR 8)
  • HY-164152
    ADC Control Human IgG1-Deruxtecan (DAR 4)

    		Antibody-Drug Conjugates (ADCs) Topoisomerase Cancer
    ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
    ADC Control Human IgG1-Deruxtecan (DAR 4)
  • HY-P99813
    Patritumab deruxtecan

    HER3-DXd; U3-1402

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .
    Patritumab deruxtecan
  • HY-P99234
    Pivekimab

    		Interleukin Related ADC Antibody Cancer
    Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .
    Pivekimab
  • HY-153360
    MC-GGFG-AM-(10Me-11F-Camptothecin)

    		Drug-Linker Conjugates for ADC Topoisomerase Cancer
    MC-GGFG-AM-(10Me-11F-Camptothecin) is a linker-payload conjugate used to synthesize ZW251. ZW251 an antibody-drug conjugate (ADC) targeting human GPC3. ZW251 consists of a humanized IgG1 antibody conjugated to a novel camptothecin-based topoisomerase 1 inhibitor, ZD06519, via a linker. The linker is the maleimide anchor and a glycyl glycyl phenylalanyl glycine (GGFG)-aminomethyl (AM) cleavable linker. ZW251 has high affinity with human and cynomolgus monkey GPC3. ZW251 displays rapid internalization in GPC3-expressing HCC cell lines, and bystander-mediated killing of GPC3 negative cancer cells .
    MC-GGFG-AM-(10Me-11F-Camptothecin)
  • HY-P991041
    Turmetabart

    Anti-SEZ6 Antibody (SC17); ABBV-011 antibody; ABBV-706 antibody

    		 ADC Antibody Cancer
    Turmetabart (Anti-SEZ6 Antibody (SC17)) is a humanized anti-SEZ6 IgG1 monoclonal antibody. Anti-SEZ6 Antibody (SC17) can be used to synthesize antibody-drug conjugates (ADC) product, ABBV-011. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Turmetabart
  • HY-164957
    Sigvotatug vedotin

    SGN-B6A; PF-08046047

    		 Antibody-Drug Conjugates (ADCs) Integrin Cancer
    SGN-B6A is an ADC, which targets integrin beta-6 (ITGB6) through human IgG1 monoclonal antibody Sigvotatug (HY-P990764), and exhibits cytotoxicity against multiple integrin beta-6-positive cancer cell through mitotic inhibitor MMAE (HY-15162) .
    Sigvotatug vedotin
  • HY-P990764
    Sigvotatug

    SGN-B6A antibody

    		 Integrin ADC Antibody Inflammation/Immunology Cancer
    Sigvotatug (SGN-B6A antibody) is a human IgG1 κ monoclonal antibody against ITGB6. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001). Sigvotatug can be used as an ADC antibody to synthesize ADC Sigvotatug vedotin (HY-164957) .
    Sigvotatug
  • HY-164668
    ADC Control Human IgG1-SN-38

    		Antibody-Drug Conjugates (ADCs) Cancer
    ADC Control Human IgG1-SN-38 is an isotype control of ADC Human IgG1-SN-38. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946).
    ADC Control Human IgG1-SN-38
  • HY-145626
    Ozuriftamab
    1 Publications Verification

    BA302

    		 ADC Antibody ROR Cancer
    Ozuriftamab is a human IgG1 kappa antibody of ROR2. Ozuriftamab can be used to synthesize ADC such as Ozuriftamab vedotin (HY-145627). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Ozuriftamab
  • HY-164154
    ADC Control Human IgG1-vcMMAF

    		Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
    ADC Control Human IgG1-vcMMAF
  • HY-P991204
    Anti-PSMA Antibody

    ARX517 antibody

    		 PSMA Cancer
    Anti-PSMA Antibody (ARX517 antibody) is a humanized IgG1 monoclonal antibody that targets PSMA. Anti-PSMA Antibody is the antibody part of the ADC molecule ARX517. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Anti-PSMA Antibody
  • HY-P99271
    Tisotumab

    Anti-human F3 Recombinant Antibody

    		 ADC Antibody Cancer
    Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab targets tissue factor (TF). Tisotumab can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab can be used for the research of solid tumors .
    Tisotumab
  • HY-P99229
    Upifitamab
    2 Publications Verification

    XMT-1535; Upinitatug

    		 ADC Antibody Cancer
    Upifitamab is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize ADC such as Upfitamab rilsodotin. Upfitamab rilsodotin can be used in research for solid tumors including high-grade serious epithelial ovarian, fallopian tube and primary peritoneal cancer (OC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Upifitamab
  • HY-164669
    ADC Control Human IgG1-DM4

    		Antibody-Drug Conjugates (ADCs) Cancer
    ADC Control Human IgG1-DM4 is an isotype control of ADC Human IgG1-DM4. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is SPDB-DM4 (HY-12460).
    ADC Control Human IgG1-DM4
  • HY-P99233
    Camidanlumab

    HuMax-TAC

    		 ADC Antibody Transmembrane Glycoprotein Interleukin Related Cancer
    Camidanlumab (HuMax-TAC) is a humanized IgG1 monoclonal antibody against CD25. Camidanlumab can be used to synthesize the ADC molecule Camidanlumab tesirine (HY-141599). Camidanlumab can be used in the research of tumors such as lymphoma and leukemia. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Camidanlumab
  • HY-P991197
    Anti-GPRC5D Antibody

    LM-305 antibody; AZD-0305 antibody

    		 CD3 Cancer
    Anti-GPRC5D Antibody (LM-305 antibody) is a humanized IgG1 monoclonal antibody that targets GPRC5D. Anti-GPRC5D Antibody is the antibody part of the ADC molecule LM-305. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-GPRC5D Antibody
  • HY-P99970
    Lifastuzumab

    		ADC Antibody Sodium Phosphate Cotransporter Cancer
    Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Lifastuzumab
  • HY-P99230
    Pinatuzumab

    		Integrin CD22 Cancer
    Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Pinatuzumab
  • HY-P991699
    Lixarkitug

    AZD9829 antibody; INT-020

    		 ADC Antibody Interleukin Related Cancer
    Lixarkitug (AZD9829 antibody; INT-020) is a humanized IgG1κ antibody targeting IL-3Ra/CD123. Lixarkitug can be conjugated with Samrotecan to form the intact ADC molecule lixarkitug samrotecan (AZD9829), which is used in studies of acute myeloid leukemia (AML) . The isotype control corresponding to Lixarkitug is Human IgG1 kappa, Isotype Control (HY-P99001).
    Lixarkitug
  • HY-164954
    ADC Control Human IgG1-McMMAF

    		Antibody-Drug Conjugates (ADCs) Cancer
    ADC Control Human IgG1-McMMAF is an antibody-drug conjugate (ADC) composed of the ADC antibody IgG1 Human IgG1 kappa, Isotype Control (HY-P99001) and the payload McMMAF (HY-15578).
    ADC Control Human IgG1-McMMAF
  • HY-150362
    ADC Control Human IgG1-tirumotecan

    		Antibody-Drug Conjugates (ADCs) Cancer
    ADC Control Human IgG1-tirumotecan is an antibody-drug conjugate (ADC). The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is TL033 TFA (HY-147340A). ADC Control Human IgG1-tirumotecan can be as a control of Sacituzumab tirumotecan (HY-164789).
    ADC Control Human IgG1-tirumotecan
  • HY-159774
    ADC Control human IgG1-DM1

    		Antibody-Drug Conjugates (ADCs) Cancer
    ADC Control human IgG1-DM1 is the ADC control, which is composed of Human IgG1 kappa, Isotype Control (HY-P99001) and the linker-payload conjugate SMCC-DM1 (HY-101070) .
    ADC Control human IgG1-DM1
  • HY-150363
    ADC Control Human IgG1-sulfo-SPDB-DM4

    		Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    ADC Control Human IgG1-sulfo-SPDB-DM4 is an antibody-drug conjugate (ADC) and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is sulfo-SPDB-DM4 (HY-101141) .
    ADC Control Human IgG1-sulfo-SPDB-DM4
  • HY-P99656
    Iladatuzumab

    MCDS0593A

    		 ADC Antibody Cancer
    Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .
    Iladatuzumab
  • HY-P99271A
    Tisotumab (powder)

    Anti-human F3 Recombinant Antibody (powder)

    		 ADC Antibody Cancer
    Tisotumab (Anti-Human F3 Recombinant Antibody) (powder) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab (powder) targets tissue factor (TF). Tisotumab (powder) can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab (powder) can be used for the research of solid tumors .
    Tisotumab (powder)
  • HY-141599
    Camidanlumab tesirine

    ADCT 301

    		 Antibody-Drug Conjugates (ADCs) Interleukin Related Cancer
    Camidanlumab tesirine (ADCT 301) is an ADC comprising HuMax-TAC, a human IgG1 mAb directed against human CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead. Camidanlumab tesirine has a drug–antibody ratio (DAR) of 2.3. Camidanlumab tesirine binds human CD25 with picomolar affinity. Camidanlumab tesirine has highly potent and selective cytotoxicity against a panel of CD25-expressing human lymphoma cell lines .
    Camidanlumab tesirine
  • HY-P991640
    Anti-TDGF1 antibody (huB3F6)

    BIIB015 antibody

    		 ADC Antibody Cancer
    Anti-TDGF1 antibody (huB3F6) (BIIB015 antibody) is a CHO-expressed human antibody that targets TDGF1. Anti-TDGF1 antibody has huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TDGF1 antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001). Anti-TDGF1 antibody (huB3F6) can be used for synthesis of ADCs .
    Anti-TDGF1 antibody (huB3F6)
  • HY-185188
    ADC Control Human IgG1-DL-01

    		Antibody-Drug Conjugates (ADCs) Others
    ADC Control Human IgG1-DL-01 is an antibody-drug conjugate (ADC) consisting of the ADC antibody Human IgG1 lambda1, Isotype Control (HY-P99992) and the linker-payload DL-01 formic (HY-155870A).
    ADC Control Human IgG1-DL-01
  • HY-185294
    ADC Control Human IgG1-ED04

    		Antibody-Drug Conjugates (ADCs) Others
    ADC Control human IgG1-ED04 is an ADC control composed of Human IgG1 kappa, Isotype Control (HY-P99001) and ADC toxin ED04 (HY-153891). It can be used as an isotype control for BL-B01D1 (HY-164702).
    ADC Control Human IgG1-ED04
  • HY-P992337
    CS5001 Antibody

    		ROR Cancer
    CS5001 Antibody is an IgG1 human monoclonal antibody targeting ROR1. CS5001 Antibody can be used for the synthesis of the ADC CS5001. It is applicable to research related to advanced solid tumors and lymphomas. The recommended isotype control is human IgG1 kappa (HY-P99001) .
    CS5001 Antibody
  • HY-P992127
    Renditatug

    BAT8008 Antibody; BAT0806

    		 TROP2 ADC Antibody Cancer
    Renditatug (BAT8008 Antibody) is an antibody targeting TROP2. Renditatug can be used for the synthesis of ADC BAT8008. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Renditatug
  • HY-P991874
    AMG-224 Antibody

    		ADC Antibody CD3 Cancer
    AMG-224 Antibody is an anti-human BCMA IgG1 antibody. AMG-224 Antibody can generate antibody drug conjugate (ADC) (AMG 224) with a tubulin inhibitor Mertansine (HY-19792). AMG-224 Antibody can be used for the study of multiple myeloma .
    AMG-224 Antibody
  • HY-P992133
    Sutantatug

    SYS6002 Antibody; CRB-701 Antibody

    		 ADC Antibody Nectin-4 Cancer
    Sutantatug (SYS6002 Antibody) is a monoclonal antibody targeting Nectin-4, and serves as the antibody moiety of the ADC CRB-701. Sutantatug is applicable to the research of Nectin-4-positive solid tumors, urothelial carcinoma and cervical cancer. The corresponding isotype control for Sutantatug is Human IgG1 kappa, Isotype Control (HY-P99001) .
    Sutantatug
  • HY-P991995
    OMTX005

    OMTX705 antibody

    		 ADC Antibody FAP Cancer
    OMTX005 (OMTX705 antibody) is a humanized anti-FAP IgG1 monoclonal antibody that specifically binds to human (EC50: 0.33 nM)/mouse (EC50: 0.14 nM) FAP proteins and FAP-positive cells. OMTX005 exhibits no cytotoxicity when used alone and fails to induce an increase in caspase 3/7 activity in relevant cells. OMTX005 can be used to synthesize the ADC molecule OMTX705 for tumor research .
    OMTX005
  • HY-185483
    AMG-172

    		Antibody-Drug Conjugates (ADCs) Transmembrane Glycoprotein Microtubule/Tubulin Cancer
    AMG-172 is an antibody-drug conjugate (ADC) composed of a fully human IgG1 monoclonal anti-CD27L antibody conjugated to DM1 (HY-19792) via the non-cleavable linker MCC. AMG-172 releases the intracellular active component Lysine-MCC-DM through catabolism. Lysine-MCC-DM inhibits the assembly and disassembly dynamics of Microtubule and induces cell arrest at metaphase. AMG-172 can be used for research on relapsed/refractory clear cell renal cell carcinoma .
    AMG-172
  • HY-P992146
    Zevontabart

    MYTX-011 Antibody; Q-397

    		 ADC Antibody c-Met/HGFR Cancer
    Zevontabart (MYTX-011 Antibody; Q-397) is a pH-dependent anti-c-MET antibody. Zevontabart regulates the trafficking process of c-MET to reduce receptor recycling, and enhances its own endocytosis and accumulation in c-MET-expressing cells. Zevontabart induces cytotoxicity in solid tumor cells and exerts anti-tumor activity in a non-small cell lung cancer xenograft mouse model. Zevontabart can be used to synthesize ADC, such as: MYTX-011. Zevontabart can be used in studies related to non-small cell lung cancer, with its corresponding isotype control being Human IgG1 kappa, Isotype Control (HY-P99001) .
    Zevontabart

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: